Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Pulmonary Hypertension - Cellular and Molecular Changes in the Lung...
share announcement

Pulmonary Hypertension - Cellular and Molecular Changes in the Lung and in the Right Ventricle

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 1 July 2024 | Viewed by 7070

Special Issue Editor

Prof. Dr. Véronique C. Freund-Michel

E-Mail Website
Guest Editor
Centre de Recherche Cardio-Thoracique de Bordeaux-INSERM U1045, Université de Bordeaux, Bordeaux, France
Interests: nerve growth factor (NGF); TrkA and p75NTR receptors; pulmonary hypertension; cardiac dysfunction and remodelling; cardiovascular and pulmonary pathophysiology and pharmacology; chronic hypoxia; animal models; cell cultures; smooth muscle cells; endothelial cells; fibroblasts; inflammation; pro-inflammatory cytokines; neurotrophins; macrophages; mast cells; pulmonary arterial remodelling; pulmonary arterial reactivity; calcium signalling; calcium sensitization mechanisms; TRP channels; Piezo channels; proliferation; migration; connexins; GAP junctions

Special Issue Information

Dear Colleagues, 

Pulmonary hypertension (PH) is a severe disease characterized by sustained elevated pulmonary arterial pressures leading to right ventricular hypertrophy, right heart failure, and patient death. Since the currently available PH treatments improve patients’ quality of life and prolong their survival but fail to reverse the disease, new and efficient treatments are urgently needed. The key pathophysiological mechanisms of PH involve pulmonary arterial remodeling, inflammation, and altered reactivity, but all the cellular and molecular changes in the lung contributing to these alterations remain unknown. Gaining a better understanding of these changes may help us to highlight new potential therapeutic targets, undoubtedly leading to new perspectives in the treatment of PH. Another current challenge in PH is developing a strategy that would also be able to decrease/delay the development of right heart failure, which is often responsible for the death of PH patients. Gaining a better understanding of the right ventricular cellular and molecular changes associated with PH would also allow us to highlight new potential therapeutic targets. The aim of this Special Issue, entitled “Pulmonary hypertension – cellular and molecular changes in the lung and in the right ventricle”, is therefore to welcome both original papers and comprehensive review papers exploring the cellular and molecular changes in the lung and/or right ventricle during pulmonary hypertension, which may lead to opening new and exciting therapeutic perspectives on this devastating disease.  

We look forward to receiving your contributions. 

Prof. Dr. Véronique C. Freund-Michel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary hypertension
  • pulmonary arterial smooth muscle cells
  • endothelial cells
  • fibroblasts
  • inflammatory cells
  • vascular remodelling
  • reactivity
  • inflammation
  • endothelial dysfunction
  • right ventricular dysfunction
  • remodelling

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 2440 KiB  
Article
Inhibition of Soluble Epoxide Hydrolase Does Not Promote or Aggravate Pulmonary Hypertension in Rats
by Matthieu Leuillier, Valentin Platel, Ly Tu, Guillaume Feugray, Raphaël Thuillet, Déborah Groussard, Hind Messaoudi, Mina Ottaviani, Mustapha Chelgham, Lionel Nicol, Paul Mulder, Marc Humbert, Vincent Richard, Christophe Morisseau, Valéry Brunel, Thomas Duflot, Christophe Guignabert and Jérémy Bellien
Cells 2023, 12(4), 665; https://doi.org/10.3390/cells12040665 - 20 Feb 2023
Viewed by 1613
Abstract
Inhibitors of soluble epoxide hydrolase (sEH), which catalyzes the hydrolysis of various natural epoxides to their corresponding diols, present an opportunity for developing oral drugs for a range of human cardiovascular and inflammatory diseases, including, among others, diabetes and neuropathic pain. However, some [...] Read more.
Inhibitors of soluble epoxide hydrolase (sEH), which catalyzes the hydrolysis of various natural epoxides to their corresponding diols, present an opportunity for developing oral drugs for a range of human cardiovascular and inflammatory diseases, including, among others, diabetes and neuropathic pain. However, some evidence suggests that their administration may precipitate the development of pulmonary hypertension (PH). We thus evaluated the impact of chronic oral administration of the sEH inhibitor TPPU (N-[1-(1-Oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl]-urea) on hemodynamics, pulmonary vascular reactivity, and remodeling, as well as on right ventricular (RV) dimension and function at baseline and in the Sugen (SU5416) + hypoxia (SuHx) rat model of severe PH. Treatment with TPPU started 5 weeks after SU5416 injection for 3 weeks. No differences regarding the increase in pulmonary vascular resistance, remodeling, and inflammation, nor the abolishment of phenylephrine-induced pulmonary artery constriction, were noted in SuHx rats. In addition, TPPU did not modify the development of RV dysfunction, hypertrophy, and fibrosis in SuHx rats. Similarly, none of these parameters were affected by TPPU in normoxic rats. Complementary in vitro data demonstrated that TPPU reduced the proliferation of cultured human pulmonary artery-smooth muscle cells (PA-SMCs). This study demonstrates that inhibition of sEH does not induce nor aggravate the development of PH and RV dysfunction in SuHx rats. In contrast, a potential beneficial effect against pulmonary artery remodeling in humans is suggested. Full article
(This article belongs to the Special Issue Pulmonary Hypertension - Cellular and Molecular Changes in the Lung and in the Right Ventricle)
►▼ Show Figures

Figure 1

18 pages, 3751 KiB  
Article
Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca2+ Influx and Akt-eNOS Pathway
by Thais Porto Ribeiro, Solène Barbeau, Isabelle Baudrimont, Pierre Vacher, Véronique Freund-Michel, Guillaume Cardouat, Patrick Berger, Christelle Guibert, Thomas Ducret and Jean-François Quignard
Cells 2022, 11(15), 2349; https://doi.org/10.3390/cells11152349 - 30 Jul 2022
Cited by 9 | Viewed by 2819
Abstract
In intrapulmonary arteries (IPAs), mechanical forces due to blood flow control vessel tone, and these forces change during pulmonary hypertension (PH). Piezo1, a stretch-activated calcium channel, is a sensor of mechanical stress present in both endothelial cells (ECs) and smooth muscle cells (SMCs). [...] Read more.
In intrapulmonary arteries (IPAs), mechanical forces due to blood flow control vessel tone, and these forces change during pulmonary hypertension (PH). Piezo1, a stretch-activated calcium channel, is a sensor of mechanical stress present in both endothelial cells (ECs) and smooth muscle cells (SMCs). The present study investigated the role of Piezo1 on IPA in the chronic hypoxia model of PH. Rats were raised in chronically hypoxic conditions for 1 (1W-CH, early stage) or 3 weeks (3W-CH, late-stage) of PH or in normoxic conditions (Nx). Immunofluorescence labeling and patch-clamping revealed the presence of Piezo1 in both ECs and SMCs. The Piezo1 agonist, Yoda1, induced an IPA contraction in Nx and 3W-CH. Conversely, Yoda1 induced an endothelial nitric oxide (eNOS) dependent relaxation in 1W-CH. In ECs, the Yoda1-mediated intracellular calcium concentration ([Ca2+]i) increase was greater in 1W-CH as compared to Nx. Yoda1 induced an EC hyperpolarization in 1W-CH. The eNOS levels were increased in 1W-CH IPA compared to Nx or 3W-CH PH and Yoda1 activated phosphorylation of Akt (Ser473) and eNOS (Ser1177). Thus, we demonstrated that endothelial Piezo1 contributes to intrapulmonary vascular relaxation by controlling endothelial [Ca2+]i, endothelial-dependent hyperpolarization, and Akt-eNOS pathway activation in the early stage of PH. Full article
(This article belongs to the Special Issue Pulmonary Hypertension - Cellular and Molecular Changes in the Lung and in the Right Ventricle)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

13 pages, 1367 KiB  
Review
Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension
by A. Dushani C. U. Ranasinghe, T. M. Parinda B. Tennakoon and Margaret A. Schwarz
Cells 2024, 13(3), 244; https://doi.org/10.3390/cells13030244 - 28 Jan 2024
Viewed by 941
Abstract
Pulmonary Hypertension (PH) is a terminal disease characterized by severe pulmonary vascular remodeling. Unfortunately, targeted therapy to prevent disease progression is limited. Here, the vascular cell populations that contribute to the molecular and morphological changes of PH in conjunction with current animal models [...] Read more.
Pulmonary Hypertension (PH) is a terminal disease characterized by severe pulmonary vascular remodeling. Unfortunately, targeted therapy to prevent disease progression is limited. Here, the vascular cell populations that contribute to the molecular and morphological changes of PH in conjunction with current animal models for studying vascular remodeling in PH will be examined. The status quo of epigenetic targeting for treating vascular remodeling in different PH subtypes will be dissected, while parallel epigenetic threads between pulmonary hypertension and pathogenic cancer provide insight into future therapeutic PH opportunities. Full article
(This article belongs to the Special Issue Pulmonary Hypertension - Cellular and Molecular Changes in the Lung and in the Right Ventricle)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

43 pages, 501 KiB  
Systematic Review
Right Ventricle and Epigenetics: A Systematic Review
by Victoria Toro, Naomie Jutras-Beaudoin, Olivier Boucherat, Sebastien Bonnet, Steeve Provencher and François Potus
Cells 2023, 12(23), 2693; https://doi.org/10.3390/cells12232693 - 23 Nov 2023
Viewed by 1017
Abstract
There is an increasing recognition of the crucial role of the right ventricle (RV) in determining the functional status and prognosis in multiple conditions. In the past decade, the epigenetic regulation (DNA methylation, histone modification, and non-coding RNAs) of gene expression has been [...] Read more.
There is an increasing recognition of the crucial role of the right ventricle (RV) in determining the functional status and prognosis in multiple conditions. In the past decade, the epigenetic regulation (DNA methylation, histone modification, and non-coding RNAs) of gene expression has been raised as a critical determinant of RV development, RV physiological function, and RV pathological dysfunction. We thus aimed to perform an up-to-date review of the literature, gathering knowledge on the epigenetic modifications associated with RV function/dysfunction. Therefore, we conducted a systematic review of studies assessing the contribution of epigenetic modifications to RV development and/or the progression of RV dysfunction regardless of the causal pathology. English literature published on PubMed, between the inception of the study and 1 January 2023, was evaluated. Two authors independently evaluated whether studies met eligibility criteria before study results were extracted. Amongst the 817 studies screened, 109 studies were included in this review, including 69 that used human samples (e.g., RV myocardium, blood). While 37 proposed an epigenetic-based therapeutic intervention to improve RV function, none involved a clinical trial and 70 are descriptive. Surprisingly, we observed a substantial discrepancy between studies investigating the expression (up or down) and/or the contribution of the same epigenetic modifications on RV function or development. This exhaustive review of the literature summarizes the relevant epigenetic studies focusing on RV in human or preclinical setting. Full article
(This article belongs to the Special Issue Pulmonary Hypertension - Cellular and Molecular Changes in the Lung and in the Right Ventricle)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop